As advised via PHARMAC tender of 30 April 2018 there is to be a change in the listing and future sole supply.

New listing from 1 October 2018 (HML only)

Flumazenil Hameln Inj 0.1 mg per ml, 5 ml 5 ampoules                                   Pharmacode 2545535                   Schedule price $66.34

Incumbent brand

Anexate Inj 40 mg per ml, 5 ml 5 ampoules                                                    Pharmacode 538248            Schedule price $85.05

Reference pricing will not apply to the incumbent which will be delisted 1 December 2018.

As of the date of this notification ProPharma / PWR cannot accept Anexate for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

Once again we need your support to ensure stock in the supply chain moves through to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author